表紙
市場調查報告書
商品編碼
971974

酒精性肝炎:市場分析,流行病學,市場預測 (2030年)

Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 146 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

主要7個國家的酒精性肝炎 (AH)的患者數,2017年時刻達到65萬1028人。還有酒精性肝炎的治療藥市場也急速擴大。

本報告提供全球主要7個國家- 美國,歐洲主要5個國家 (EU5:法國、德國、義大利、西班牙、英國 ),日本 - 的酒精性肝炎 (AH)的疫情趨勢今後的市場預測相關分析,疾病概要和市場基本結構,目前治療方法和未滿足需求,患病人數趨勢預測,已上市/臨床實驗中的治療藥的簡介,全球整體/各國的市場規模 (過去3年、今後11年份),主要的推動及阻礙市場要素等資訊彙整,為您概述為以下內容。

目錄

第1章 主要考察

第2章 酒精性肝炎:摘要整理

第3章 酒精性肝炎的SWOT分析

第4章 酒精性肝炎:市場概要

  • 整體市場佔有率結構 (2017年)
  • 整體市場佔有率結構 (2030年)

第5章 酒精性肝炎:疾病概要

  • 簡介
  • 酒精性肝疾病
  • 病因
  • 症狀
  • 臨床表現
  • 組織病理學
  • 病因
  • 預後
  • 危險因素
  • 診斷
    • 鑑別診斷

第6章 流行病學和患者人口

第7章 主要7個國家的流行病學的分析

  • 假設和理論性根據
  • 中度∼重度的酒精性肝炎已診斷的患者數:世界主要7個國家
  • 美國
    • 酒精性肝炎 (AH)的患病者總數
    • 酒精性肝炎 (AH)的已受診患病人數
    • 酒精性肝炎 (AH)的患病者總數:男女
    • 酒精性肝炎 (AH)的患病者總數:各重症度
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 酒精性肝炎的治療

  • 治療指南

第9章 未滿足需求

第10章 AH貢獻的組織

第11章 案例研究

  • 酒精性肝炎-集中管理的情況
  • 粒細胞刺激治療的重度的酒精性肝炎的病例
  • 重度的酒精性肝炎:顯著上升的鹼性磷酸酶伴隨的非典型症狀
  • 意外組織型的酒精性肝炎:病例報告

第12章 KOL的見解

第13章 新治療藥

  • DUR 928:DURECT Corporation
    • 產品說明
    • 臨床開發
    • 安全性和有效性
  • Canakinumab:Novartis

第14章 酒精性肝炎 (AH):主要7個國家的市場分析

  • 主要調查結果
  • 主要7個國家的酒精性肝炎 (AH)的市場規模

第15章 主要7個國家的市場展望

  • 美國的市場規模
    • 酒精性肝炎 (AH)的市場規模:全體
    • 酒精性肝炎 (AH)的市場規模:各治療藥物
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第16章 市場促進因素

第17章 市場阻礙因素

第18章 償付

第19章 附錄

第20章 DelveInsight的服務內容

第21章 免責聲明

第22章 關於DelveInsight

目錄
Product Code: DIMI0698

DelveInsight's 'Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Alcoholic Hepatitis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Alcoholic Hepatitis market report provides analysis regarding current treatment practices, emerging drugs-like DUR-928 (Durect Corporation), and Canakinumab (Novartis), potential therapies, market share of the individual therapies, historical, current, and forecasted Alcoholic Hepatitis market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Alcoholic Hepatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Alcoholic Hepatitis - Disease Understanding and Treatment Algorithm

Alcoholic Hepatitis Overview

Alcoholic hepatitis (AH), as the name suggests, is hepatitis - inflammation of the liver - due to excessive intake of alcohol. Patients typically have a history of decades of heavy alcohol intake, about 8-10 drinks per day. It is usually found in association with fatty liver, an early stage of alcoholic liver disease, and may contribute to fibrosis progression, leading to cirrhosis.

Signs and symptoms of alcoholic hepatitis include jaundice (yellowing of the skin and eyes), ascites (fluid accumulation in the abdominal cavity), fatigue, and hepatic encephalopathy (brain dysfunction due to liver failure). Mild cases are self-limiting, but severe cases have a high risk of death.

Diagnosing AH can be challenging as the disease has widely varying presentations and, in severe cases, can mimic a bacterial infection and/or biliary obstruction. A detailed and thorough history remains the cornerstone of diagnosis. Obtaining such a history can be rather difficult if patients feel ashamed about their drinking habits. Often, lengthy discussions are required to reveal the full extent of alcohol intake.

Alcoholic Hepatitis Treatment

This chapter covers the details of conventional and current medical therapies available in the Alcoholic Hepatitis market to treat the condition. It also provides the country-wise Alcoholic Hepatitis treatment guidelines across the United States, Europe, and Japan.

DelveInsight's Alcoholic Hepatitis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Alcoholic Hepatitis treatment algorithms and treatment guidelines in the US, Europe, and Japan.

In most patients with alcoholic hepatitis, the illness is mild. The short-term prognosis is good, and no specific treatment is required. Hospitalization is not always necessary. Alcohol use must be stopped, and care should be taken to ensure good nutrition; providing supplemental vitamins and minerals, including folate and thiamine, is reasonable. Coagulopathic patients should receive vitamin K parentally. Anticipate symptoms of alcohol withdrawal, and manage them appropriately. In contrast, patients with severe acute alcoholic hepatitis are at a high risk of early death, at a 50% or greater rate within 30 days.

The use of medications in alcoholic hepatitis has been considered controversial. Many treatments discussed in the Medication section are still investigational. However, according to the 2010 American Association for the Study of Liver Diseases (AASLD) alcoholic liver disease (ALD) guideline: (1) Naltrexone or acamprAHte may be used, in addition to counseling, to assist patients who have achieved abstinence to avoid relapsing; and (2) in patients with severe disease (Maddrey discriminant function [MDF] score ≥32), unless steroids are contraindicated, prednisolone should be considered. Pentoxifylline may be considered, especially if prednisolone cannot be used. Prednisolone and pentoxifylline are recommended to treat severe alcoholic hepatitis, but uncertainty about their benefit persists.

Alcoholic Hepatitis Epidemiology

The Alcoholic Hepatitis epidemiology chapters provide insights about historical and current Alcoholic Hepatitis patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Alcoholic Hepatitis epidemiology is segmented by AH's total prevalent cases, diagnosed cases of AH, gender-specific cases of AH, and severity-specific cases of AH. The report includes a thorough analysis of all segmentations.

According to DelveInsight's estimate, diagnosed moderate to severe Alcoholic Hepatitis cases in 7MM countries were found to be 6,51,028 cases in 2017. Among all the seven major markets, the United States accounts for the highest number of Alcoholic Hepatitis cases.

In the US, the diagnosed prevalence of Alcoholic Hepatitis was 2,37,284 cases in 2017, whereas Japan had 1,58,709 cases.

Alcoholic Hepatitis Drug Chapters

The drug chapter segment of the Alcoholic Hepatitis report encloses the detailed analysis of Alcoholic Hepatitis pipeline drug. It also helps understand the Alcoholic Hepatitis clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.

To date, the use of medications in alcoholic hepatitis has been considered controversial. Many treatments discussed in this section remain investigational. Naltrexone or acamprAHte, prednisolone can be considered. Apart from these, many drugs are still under trials or need more proper studies to prove efficacy. Thus, any significant development in this direction is expected to create a tectonic impact on the existing market scenario during our forecast period.

Alcoholic Hepatitis Market Outlook

The Alcoholic Hepatitis market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounts for the largest Alcoholic Hepatitis market size, with USD 2.1 million, while Japan's Alcoholic Hepatitis market size was USD 0.5 million in 2017.

Alcoholic Hepatitis Drugs Uptake

This section focuses on the uptake of the potential drugs in the Alcoholic Hepatitis market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Alcoholic Hepatitis market uptake by drugs, patient uptake by therapies, and drug sale.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of the Alcoholic Hepatitis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Alcoholic Hepatitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Alcoholic Hepatitis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers Alcoholic Hepatitis collaborations, acquisition and merger, licensing, patent details, and other information for Alcoholic Hepatitis emerging therapies.

Reimbursement Scenario in Alcoholic Hepatitis

Approaching reimbursement, proactively, can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in the Alcoholic Hepatitis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Alcoholic Hepatitis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, the Alcoholic Hepatitis market scenario is expected to alter across the 7MM due to the launch of a few therapies covering the drawbacks of the standard of care.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Alcoholic Hepatitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Alcoholic Hepatitis Pipeline Analysis
  • Alcoholic Hepatitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alcoholic Hepatitis Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Alcoholic Hepatitis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Alcoholic Hepatitis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Alcoholic Hepatitis market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Alcoholic Hepatitis total market size and market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Alcoholic Hepatitis market size during the forecast period (2017-2030)?
  • At what CAGR, the Alcoholic Hepatitis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Alcoholic Hepatitis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Alcoholic Hepatitis market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of Alcoholic Hepatitis?
  • What is the historical Alcoholic Hepatitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Alcoholic Hepatitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Alcoholic Hepatitis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Alcoholic Hepatitis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for Alcoholic Hepatitis treatment, along with the approved therapy?
  • What are the current treatment guidelines for treating Alcoholic Hepatitis in the USA, Europe, and Japan?
  • What is the Alcoholic Hepatitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Alcoholic Hepatitis?
  • How many therapies are developed by each company for Alcoholic Hepatitis treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for Alcoholic Hepatitis treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alcoholic Hepatitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Alcoholic Hepatitis and their status?
  • What are the key designations that have been granted for the emerging therapies for Alcoholic Hepatitis?
  • What are the global historical and forecasted market of Alcoholic Hepatitis?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Alcoholic Hepatitis market
  • To understand the future market competition in the Alcoholic Hepatitis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Alcoholic Hepatitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Alcoholic Hepatitis market
  • To understand the future market competition in the Alcoholic Hepatitis market

Which geography accounted for the largest Alcoholic Hepatitis market size?

The United States accounted for the largest Alcoholic Hepatitis market size.

What is the forecasted Alcoholic Hepatitis market size in 2030?

DelveInsight estimates an increase in Alcoholic Hepatitis Market Size during the study period, 2017-2030

What is the present Alcoholic Hepatitis market drivers?

The upcoming pipeline, novel treatment options, patient pool, and technological advancements are likely to drive the AH market.

What is the Alcoholic Hepatitis market barriers?

Key barriers to drug development, mortality, and treatment cost are likely to block the market growth.

How many companies are developing drugs for Alcoholic Hepatitis?

Some companies that are working robustly in providing effective treatment to the individuals suffering from AH like, Durect and Novartis.

Which are the leading companies in the Alcoholic Hepatitis market?

Key Players - Durect corporation and Novartis.

How is epidemiology segmented for Alcoholic Hepatitis?

Total prevalent cases of AH diagnosed prevalent cases of AH, gender-specific cases of AH, and severity-specific cases of Alcoholic Hepatitis.

Table of Contents

1 Key Insights

2 Executive Summary of Alcoholic Hepatitis

3 SWOT Analysis for Alcoholic Hepatitis

4 Alcoholic Hepatitis Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of Alcoholic Hepatitis in 2017
  • 4.2 Market Share (%) Distribution of Alcoholic Hepatitis in 2030

5 Alcoholic Hepatitis: Disease Overview

  • 5.1 Introduction
  • 5.2 Alcoholic Liver Disease
  • 5.3 Etiology
  • 5.4 Signs and Symptoms
  • 5.5 Clinical Presentation
  • 5.6 Histopathology
  • 5.7 Pathogenesis
  • 5.8 Prognosis
  • 5.9 Risk Factors
  • 5.1 Diagnosis
    • 5.10.1 Differential Diagnosis

6 Epidemiology and Patient Population

  • 6.1 Key Findings

7 7MM Epidemiology

  • 7.1 Assumptions and rationale
  • 7.2 Diagnosed Moderate to Severe Cases of Alcoholic Hepatitis (AH) in 7MM
  • 7.3 United States
    • 7.3.1 Total Prevalent cases of Alcoholic Hepatitis (AH) in the United States
    • 7.3.2 Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in the United States
    • 7.3.3 Gender-specific cases of Alcoholic Hepatitis (AH) in the United States
    • 7.3.4 Severity-specific cases of Alcoholic Hepatitis (AH) in the United States
  • 7.4 Germany
    • 7.4.1 Total Prevalent cases of Alcoholic Hepatitis (AH) in Germany
    • 7.4.2 Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Germany
    • 7.4.3 Gender-specific cases of Alcoholic Hepatitis (AH) in Germany
    • 7.4.4 Severity-specific cases of Alcoholic Hepatitis (AH) in Germany
  • 7.5 France
    • 7.5.1 Total Prevalent cases of Alcoholic Hepatitis (AH) in France
    • 7.5.2 Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in France
    • 7.5.3 Gender-specific cases of Alcoholic Hepatitis (AH) in France
    • 7.5.4 Severity-specific cases of Alcoholic Hepatitis (AH) in France
  • 7.6 Italy
    • 7.6.1 Total Prevalent cases of Alcoholic Hepatitis (AH) in Italy
    • 7.6.2 Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Italy
    • 7.6.3 Gender-specific cases of Alcoholic Hepatitis (AH) in Italy
    • 7.6.4 Severity-specific cases of Alcoholic Hepatitis (AH) in Italy
  • 7.7 Spain
    • 7.7.1 Total Prevalent cases of Alcoholic Hepatitis (AH) in Spain
    • 7.7.2 Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Spain
    • 7.7.3 Gender-specific cases of Alcoholic Hepatitis (AH) in Spain
    • 7.7.4 Severity-specific cases of Alcoholic Hepatitis (AH) in Spain
  • 7.8 United Kingdom
    • 7.8.1 Total Prevalent cases of Alcoholic Hepatitis (AH) in the United Kingdom
    • 7.8.2 Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in the United Kingdom
    • 7.8.3 Gender-specific cases of Alcoholic Hepatitis (AH) in the United Kingdom
    • 7.8.4 Severity-specific cases of Alcoholic Hepatitis (AH) in the United Kingdom
  • 7.9 Japan
    • 7.9.1 Total Prevalent cases of Alcoholic Hepatitis (AH) in Japan
    • 7.9.2 Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Japan
    • 7.9.3 Gender-specific cases of Alcoholic Hepatitis (AH) in Japan
    • 7.9.4 Severity-specific cases of Alcoholic Hepatitis (AH) in Japan

8 Treatment of Alcoholic Hepatitis

  • 8.1 Treatment Guidelines

9 Unmet Needs

10 Organizations contributing toward AH

11 Case studies

  • 11.1 Alcoholic hepatitis - the case for intensive management
  • 11.2 Case of severe alcoholic hepatitis treated with granulocytapheresis
  • 11.3 Severe Alcoholic Hepatitis: Atypical Presentation with Markedly Elevated Alkaline Phosphatase
  • 11.4 Alcoholic Hepatitis with an Unexpected Histology: A Case Report

12 KOL Views

13 Emerging Therapies

  • 13.1 DUR 928: DURECT Corporation
    • 13.1.1 Product Description
    • 13.1.2 Clinical Development
    • 13.1.3 Safety and Efficacy
  • 13.2 Canakinumab: Novartis
    • 13.2.1 Product Description
    • 13.2.2 Clinical Development

14 Alcoholic Hepatitis (AH): Seven Major Market Analysis

  • 14.1 Key Findings
  • 14.2 Market Size of Alcoholic Hepatitis (AH) in 7MM

15 Seven Major Market Outlook

  • 15.1 The United States Market Size
    • 15.1.1 Total Market Size of Alcoholic Hepatitis (AH) in the United States
    • 15.1.2 Total Market Size of Alcoholic Hepatitis (AH) by Therapies in the United States
  • 15.2 Germany
    • 15.2.1 The total market size of Alcoholic Hepatitis (AH) in Germany
    • 15.2.2 Market size of Alcoholic Hepatitis (AH) by Therapies in Germany
  • 15.3 France
    • 15.3.1 The total market size of Alcoholic Hepatitis (AH) in France
    • 15.3.2 Market size of Alcoholic Hepatitis (AH) by Therapies in France
  • 15.4 Italy
    • 15.4.1 The total market size of Alcoholic Hepatitis (AH) in Italy
    • 15.4.2 Market size of Alcoholic Hepatitis (AH) by Therapies in Italy
  • 15.5 Spain
    • 15.5.1 Total Market Size of Alcoholic Hepatitis (AH) in Spain
    • 15.5.2 Market size of Alcoholic Hepatitis (AH) by Therapies in Spain
  • 15.6 United Kingdom
    • 15.6.1 The total market size of Alcoholic Hepatitis (AH) in the United Kingdom
    • 15.6.2 Market size of Alcoholic Hepatitis (AH) by Therapies in the UK
  • 15.7 Japan
    • 15.7.1 The total market size of Alcoholic Hepatitis (AH) in Japan
    • 15.7.2 Market size of Alcoholic Hepatitis (AH) by Therapies in Japan

16 Market Drivers

17 Market Barriers

18 Reimbursement

19 Appendix

  • 19.1 Report Methodology
  • 19.2 References

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

List of Tables

  • Table 1: Alcoholic Hepatitis Signs and Symptoms
  • Table 2: Common signs and symptoms amongst hospitalized patients with alcoholic hepatitis
  • Table 3: Diagnosed Moderate to Severe Cases of Alcoholic Hepatitis (AH) in 7MM (2017-2030)
  • Table 4: Total Prevalent cases of Alcoholic Hepatitis (AH) in the United States (2017-2030)
  • Table 5: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in the US (2017-2030)
  • Table 6: Gender-specific cases of Alcoholic Hepatitis (AH) in the US (2017-2030)
  • Table 7: Severity-specific cases of Alcoholic Hepatitis (AH) in the US (2017-2030)
  • Table 8: Total Prevalent cases of Alcoholic Hepatitis (AH) in Germany (2017-2030)
  • Table 9: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Germany (2017-2030)
  • Table 10: Gender-specific cases of Alcoholic Hepatitis (AH) in Germany (2017-2030)
  • Table 11: Severity-specific cases of Alcoholic Hepatitis (AH) in Germany (2017-2030)
  • Table 12: Total Prevalent cases of Alcoholic Hepatitis (AH) in France (2017-2030)
  • Table 13: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in France (2017-2030)
  • Table 14: Gender-specific cases of Alcoholic Hepatitis (AH) in France (2017-2030)
  • Table 15: Severity-specific cases of Alcoholic Hepatitis (AH) in France (2017-2030)
  • Table 16: Total Prevalent cases of Alcoholic Hepatitis (AH) in Italy (2017-2030)
  • Table 17: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Italy (2017-2030)
  • Table 18: Gender-specific cases of Alcoholic Hepatitis (AH) in Italy (2017-2030)
  • Table 19: Severity-specific cases of Alcoholic Hepatitis (AH) in Italy (2017-2030)
  • Table 20: Total Prevalent cases of Alcoholic Hepatitis (AH) in Spain (2017-2030)
  • Table 21: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in the US (2017-2030)
  • Table 22: Gender-specific cases of Alcoholic Hepatitis (AH) in Spain (2017-2030)
  • Table 23: Severity-specific cases of Alcoholic Hepatitis (AH) in Spain (2017-2030)
  • Table 24: Total Prevalent cases of Alcoholic Hepatitis (AH) in the United Kingdom (2017-2030)
  • Table 25: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in the UK (2017-2030)
  • Table 26: Gender-specific cases of Alcoholic Hepatitis (AH) in the UK (2017-2030)
  • Table 27: Severity-specific cases of Alcoholic Hepatitis (AH) in the UK (2017-2030)
  • Table 28: Total Prevalent cases of Alcoholic Hepatitis (AH) in Japan (2017-2030)
  • Table 29: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Japan (2017-2030)
  • Table 30: Gender-specific cases of Alcoholic Hepatitis (AH) in Japan (2017-2030)
  • Table 31: Severity-specific cases of Alcoholic Hepatitis (AH) in Japan (2017-2030)
  • Table 32: Current recommendations for the diagnosis and treatment of acute alcoholic hepatitis (AH)
  • Table 33: DUR-928, Product Description
  • Table 34: DUR-928, Clinical Trial Description, 2020
  • Table 35: Canakinumab, Product Description
  • Table 36: Canakinumab, Clinical Trial Description, 2020
  • Table 37: Market Size of Alcoholic Hepatitis (AH) in 7MM in USD Million (2017-2030)
  • Table 38: The US Market Size of Alcoholic Hepatitis (AH) in USD Million (2017-2030)
  • Table 39: US Market Size of Alcoholic Hepatitis (AH) in USD Million (2017-2030)
  • Table 40: Market Size of Alcoholic Hepatitis (AH) in Germany, USD Millions (2017-2030)
  • Table 41: Germany Market Size of Alcoholic Hepatitis (AH) by Therapies in USD Million (2017-2030)
  • Table 42: Market Size of Alcoholic Hepatitis (AH) associated in France, USD Millions (2017-2030)
  • Table 43: France Market Size of Alcoholic Hepatitis (AH) by Therapies in USD Million (2017-2030)
  • Table 44: Market Size of Alcoholic Hepatitis (AH) in Italy, USD Millions (2017-2030)
  • Table 45: Italy Market Size of Alcoholic Hepatitis (AH) by Therapies in USD Million (2017-2030)
  • Table 46: Market Size of Alcoholic Hepatitis (AH) in Spain, USD Millions (2017-2030)
  • Table 47: Spain Market Size of Alcoholic Hepatitis (AH) by Therapies in USD Million (2017-2030)
  • Table 48: Market Size of Alcoholic Hepatitis (AH) in the UK, USD Millions (2017-2030)
  • Table 49: UK Market Size of Alcoholic Hepatitis (AH) by Therapies in USD Million (2017-2030)
  • Table 50: Market Size of Alcoholic Hepatitis (AH) in Japan, USD Millions (2017-2030)
  • Table 51: Japan Market Size of Alcoholic Hepatitis (AH) by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: Spectrum of alcoholic liver disease.
  • Figure 2: Histopathology of alcoholic hepatitis
  • Figure 3: Pathophysiology of Alcohol-Induced Liver Injury
  • Figure 4: Mechanisms of alcoholic liver disease
  • Figure 5: Pathogenesis of alcoholic hepatitis
  • Figure 6: Diagnosed Moderate to Severe Cases of Alcoholic Hepatitis (AH) in 7MM (2017-2030)
  • Figure 7: Total Prevalent Cases of AH in the United States (2017-2030)
  • Figure 8: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in the US (2017-2030)
  • Figure 9: Gender-specific cases of Alcoholic Hepatitis (AH) in the US (2017-2030)
  • Figure 10: Severity-specific cases of Alcoholic Hepatitis (AH) in the US (2017-2030)
  • Figure 11: Total Prevalent cases of Alcoholic Hepatitis (AH) in Germany (2017-2030)
  • Figure 12: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Germany (2017-2030)
  • Figure 13: Gender-specific cases of Alcoholic Hepatitis (AH) in Germany (2017-2030)
  • Figure 14: Severity-specific cases of Alcoholic Hepatitis (AH) in Germany (2017-2030)
  • Figure 15: Total Prevalent cases of Alcoholic Hepatitis (AH) in France (2017-2030)
  • Figure 16: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in France (2017-2030)
  • Figure 17: Gender-specific cases of Alcoholic Hepatitis (AH) in France (2017-2030)
  • Figure 18: Severity-specific cases of Alcoholic Hepatitis (AH) in France (2017-2030)
  • Figure 19: Total Prevalent cases of Alcoholic Hepatitis (AH) in Italy (2017-2030)
  • Figure 20: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Italy (2017-2030)
  • Figure 21: Gender-specific cases of Alcoholic Hepatitis (AH) in Italy (2017-2030)
  • Figure 22: Severity-specific cases of Alcoholic Hepatitis (AH) in Italy (2017-2030)
  • Figure 23: Total Prevalent cases of Alcoholic Hepatitis (AH) in Spain (2017-2030)
  • Figure 24: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Spain (2017-2030)
  • Figure 25: Gender-specific cases of Alcoholic Hepatitis (AH) in Spain (2017-2030)
  • Figure 26: Severity-specific cases of Alcoholic Hepatitis (AH) in Spain (2017-2030)
  • Figure 27: Total Prevalent cases of Alcoholic Hepatitis (AH) in the UK (2017-2030)
  • Figure 28: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in the UK (2017-2030)
  • Figure 29: Gender-specific cases of Alcoholic Hepatitis (AH) in the UK (2017-2030)
  • Figure 30: Severity-specific cases of Alcoholic Hepatitis (AH) in the UK (2017-2030)
  • Figure 31: Total Prevalent cases of Alcoholic Hepatitis (AH) in Japan (2017-2030)
  • Figure 32: Diagnosed Prevalent cases of Alcoholic Hepatitis (AH) in Japan (2017-2030)
  • Figure 33: Gender-specific cases of Alcoholic Hepatitis (AH) in Japan (2017-2030)
  • Figure 34: Severity-specific cases of Alcoholic Hepatitis (AH) in Japan (2017-2030)
  • Figure 35: Proposed algorithm for management of patients with alcoholic hepatitis
  • Figure 36: Unmet Needs
  • Figure 37: Market Size of Alcoholic Hepatitis (AH) in USD Million (2017-2030)
  • Figure 38: Market Size of Alcoholic Hepatitis (AH) in the US, USD Millions (2017-2030)
  • Figure 39: Market Size of Alcoholic Hepatitis (AH) in the US by therapies, USD Millions (2017-2030)
  • Figure 40: Market Size of Alcoholic Hepatitis (AH) in Germany, USD Millions (2017-2030)
  • Figure 41: Market Size of Alcoholic Hepatitis (AH) in Germany by therapies, USD Millions (2017-2030)
  • Figure 42: Market Size of Alcoholic Hepatitis (AH) in France, USD Millions (2017-2030)
  • Figure 43: Market Size of Alcoholic Hepatitis (AH) in France by therapies, USD Millions (2017-2030)
  • Figure 44: Market Size of Alcoholic Hepatitis (AH) in Italy, USD Millions (2017-2030)
  • Figure 45: Market Size of Alcoholic Hepatitis (AH) in Italy by therapies, USD Millions (2017-2030)
  • Figure 46: Market Size of Alcoholic Hepatitis (AH) in Spain, USD Millions (2017-2030)
  • Figure 47: Market Size of Alcoholic Hepatitis (AH) in Spain by therapies, USD Millions (2017-2030)
  • Figure 48: Market Size of Alcoholic Hepatitis (AH) in the UK, USD Millions (2017-2030)
  • Figure 49: Market Size of Alcoholic Hepatitis (AH) in the UK by therapies, USD Millions (2017-2030)
  • Figure 50: Market Size of Alcoholic Hepatitis (AH) in Japan, USD Millions (2017-2030)
  • Figure 51: Market Size of Alcoholic Hepatitis (AH) in Japan by therapies, USD Millions (2017-2030)
  • Figure 52: Market Drivers
  • Figure 53: Market Barriers